论文部分内容阅读
目的 制备99mTc-CL3-Bt并对其质量控制、生物分布进行研究。方法 将单抗CL3生物素（Bt）化，以2-巯基乙醇（2-ME）还原后以直接法进行99mTc 标记。以细胞结合实验测定并比较99mTc-CL3-Bt 和99mTc-CL3的免疫活性；然后将两种标记物注入荷大肠癌裸鼠模型，6 h后处死裸鼠，计算并比较99mTc-CL3-Bt 和99mTc-CL3在体内的每克组织摄取分数（ID%/g）值和肿瘤ID%/g/其它组织ID%/g（T/NT）比值。结果99mTc-CL3-Bt和99mTc-CL3的细胞结合率分别为90%、94%；在瘤体的ID%/g值分别为（6.3±1.1）、（6.7±0.9），二者无显著差异（t=0.6293, P>0.05）；瘤/血比值分别为（0.70±0.24）、（0.80±0.12），二者亦无显著差异（t=0.8333, P>0.05）。结论 99mTc-CL3-Bt免疫活性高，能特异性被肿瘤摄取，可广泛用于临床放射免疫显像研究。
Objective To prepare 99mTc-CL3-Bt and study its quality control and biodistribution. Methods Monoclonal antibody CL3 biotin (Bt) was transformed to 2-mercaptoethanol (2-ME) and then directly labeled with 99mTc. The binding activities of 99mTc-CL3-Bt and 99mTc-CL3 were measured by cell binding assay. The two markers were then injected into nude mice bearing colorectal cancer and the mice were killed 6 h later. The 99mTc-CL3-Bt and 99mTc- In vivo, 99mTc-CL3 incorporates fractional (ID% / g) values and tumor ID% / g / other tissue ID% / g (T / NT) ratios. Results The cell binding rates of 99mTc-CL3-Bt and 99mTc-CL3 were 90% and 94%, respectively. The ID% / g values of the tumors were (6.3 ± 1.1) and (6.7 ± 0.9) (T = 0.6293, P> 0.05). The tumor / blood ratios were (0.70 ± 0.24) and (0.80 ± 0.12) respectively, with no significant difference (t = 0.8333, P> 0.05). Conclusion 99mTc-CL3-Bt has high immunocompetence and specific tumor uptake, which can be widely used in clinical radioimmunoimaging studies.